ELEVATING EXPECTATIONS
IN PET CARE

PetMedix is delivering the next generation of proven monoclonal antibody technology to provide unprecedented therapeutic options for pets.

Read More

OUR STORY

PetMedix leverages an experienced scientific team and decades of human clinical research to develop fully species-specific, naturally generated therapeutic antibodies for pets. Here are some key moments in the company’s development and growth.

March 2014
PetMedix founder, Prof Allan Bradley FRS, publishes complete humanization of the mouse immunoglobulin locus in Nature
September 2017
PetMedix founder, Dr Jolyon Martin, publishes first comprehensive annotation of canine immunoglobulin loci in Immunogenetics
November 2017
Completion of PhD project adapting the transgenic platform from human to canine at Wellcome Sanger Institute
January 2018
Formation of PetMedix as a company
January 2019
Size of company: 12 staff
February 2019
£8million series A funding secured
February 2019
Shortlisted to present at the Animal Health Investment Europe Innovation Showcase
April 2019
Dr Fabian Kausche and Dr Cindy Cole join the Board of Directors
August 2019
Presented at Kansas City Investment Forum on future solutions for pet health
December 2019
Dr Dave Lowery joins the company
January 2020
Size of company: 24 staff
February 2020
Animal Pharm 'Best Start-up 2019' award winner
April 2020
Move to Babraham Research Campus
May 2020
Funding from Cambridge Innovation Capital secured
June 2020
Judged as ‘One to Watch’ in the global Nature Spinoff Awards
October 2020
Size of company: 32 staff
November 2020
Dr Amy Li, PetMedix’s head of Research and Innovation named in Movers and Shakers in BioBusiness 2020 report
January 2021
PetMedix enters into partnership with Boehringer Ingelheim
April 2021
Dr Jolyon Martin, co-Founder and Head of Business Development, named in Forbes 30 under 30 Europe List for Science and Healthcare 2021
June 2021
PetMedix completes Ky9 platform
antibody
July 2021
PetMedix antibodies outperform benchmarks in canine study
September 2021
Dr Amy Li, PetMedix head of Research and Development, reveals secrets of DNA methylation in early development
September 2021
PetMedix raises $37M Series B
January 2022
PetMedix enters into antibody discovery collaboration with Zoetis
July 2022
PetMedix founders develop novel antibody sequencing protocol and use it to investigate canine lymphoma
December 2022
Grant of first PetMedix Patent
August 2023
PetMedix is acquired by Zoetis, the world’s biggest animal health pharma company

Welcome to PetMedix

Step into our research hub and meet some of our talented team

This footage was filmed in November 2020

Latest News

Twitter feed is not available at the moment.

Featured in

Vet Report
Maddyness
Cambridge Network
Opera News
Pitchbook
vetpol
Angel News
Pet Gazette
PetMedix
Facebook-f Twitter Linkedin-in Instagram

Overview

Our Science

Get Involved

Contact

The Glenn Berge Building,
Babraham Research Campus, Babraham, Cambridge 
CB22 3FH

EMAIL: info@petmedix.com

TEL: +44 (0) 1223 734140

Copyright © 2024 PetMedix Ltd.

Scroll to Top

Last call!
Our final days on this website are approaching.

Stay connected with us at Zoetis.com
Thank you for your support.

Linkedin-in Facebook-f X-twitter

As we prepare to bid farewell to this website on May 31, 2024, we want to make sure you stay connected with us.

For the latest news, updates,
and content find us at Zoetis.com

Linkedin-in Facebook-f X-twitter

As we join forces with Zoetis, we've made the decision to sunset this website on
May 31, 2024

We want to thank each and every one of our followers for being part of this journey.

You can stay connected with us at Zoetis.com

Linkedin-in Facebook-f X-twitter